Conditions: Prostate Cancer
Keywords: Prostate Cancer Adenocarcinoma Prostate-Specific Antigen metastatic male HRPC DACi
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 35
Healthy volunteers: no

Brief summary:
This Phase II single dose study was designed to characterize the safety, tolerability, and efficacy of intravenous (i.v.) panobinostat as a single-agent treatment in participants with hormone refractory prostate cancer.

Detailed description:

Arms:
arm 1: Participants with metastatic hormone refractory prostate cancer received 20 milligrams per meter square (mg/m\^2) of panobinostat intravenously (i.v.) on Days 1 and 8 of a 21-day cycle. Treatment continued until disease progression as per investigator, intolerable toxicity, start of new cancer therapy, death, or withdrawal of consent.

Interventions: intervention 1: Panobinostat
Intervention descriptions: intervention 1: None

Protocol document: